SecBot SecBot
PRESS-RELEASE ·Filed Mar 27, 2026

VOR

Vor Biopharma
NEUTRAL
Impact 5/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor for SEC filing of the resale registration statement and any updates on clinical trial progress in myasthenia gravis and Sjögren’s disease. Assess whether future capital raises are likely given current runway.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$14.48
T+0 close · Mar 27, 2026 · via day close
Latest settled
+0.07%
T+60 · $14.49
Vs SPY
−16.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $14.48entry
  2. T+1 · 8mo ago +1.52%α +1.88% · $14.70
  3. T+5 · 8mo ago +12.36%α +8.50% · $16.27
  4. T+20 · 7mo ago −2.49%α −15.23% · $14.12
  5. T+60 · 5mo ago +0.07%α −16.00% · $14.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vor Biopharma announced a private placement of 5,338,078 shares at $14.05 per share, raising approximately $75 million in gross proceeds. The financing, led by new investor TCGX, will be used to advance clinical development of telitacicept in myasthenia gravis and primary Sjögren’s disease, among other corporate purposes.

Key Financial Metrics

Deal Value
$75.0M

Key Facts

  • Vor Biopharma is conducting a private placement of 5,338,078 shares at $14.05 per share.
  • Gross proceeds are expected to be approximately $75 million, before expenses.
  • The financing is led by new investor TCGX; no placement agent was used.
  • Proceeds will fund Phase 3 trials in myasthenia gravis and primary Sjögren’s disease, business development, and general corporate purposes.
  • A registration rights agreement requires Vor Bio to file a resale registration statement with the SEC.

Financial Impact

$75 million gross proceeds from issuance of ~5.34M shares, representing ~9.5% dilution based on current market cap of $563M

dilutioncashequity

Risk Factors

  • Dilution to existing shareholders from issuance of new shares.
  • Execution risk in clinical development of telitacicept despite promising forward-looking statements.
  • Market conditions could affect timing or completion of the offering despite announced agreement.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263720

Track record

17 reports on VOR

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +70.35% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.97 Now $18.97 −0.00% settles Nov 18
  2. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.32 to $19.42 Now $18.97 −1.81% ▲ +0.52% +0.88% vs SPY
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.66 to $19.88 Now $18.97 +1.66% ▲ +6.54% +6.23% vs SPY
  4. Oct 30, 202617d ago 424B5 Bearish 4/10 Entry $19.68 to $19.25 Now $18.97 +3.61% ▲ +2.19% +1.71% vs SPY
  5. Oct 30, 202617d ago Press Release Neutral 4/10 Entry $19.68 to $19.25 Now $18.97 −3.61% ▼ −2.19% −1.71% vs SPY
  6. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $18.26 to $18.33 Now $18.97 +3.89% ▲ +0.38% −0.33% vs SPY
  7. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $18.31 to $18.78 Now $18.97 +3.60% ▲ +2.57% +2.81% vs SPY
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $18.33 to $19.08 Now $18.97 +3.49% ▲ +4.09% +4.30% vs SPY
  9. Aug 11, 202613w ago Press Release Neutral 3/10 Entry $23.37 to $22.34 Now $18.97 −18.83% ▼ −4.41% −4.66% vs SPY
  10. Jul 9, 202618w ago 3 Neutral 2/10 Entry $19.14 to $18.03 Now $18.97 −0.89% ▼ −5.80% −5.03% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 27, 2026